Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center

Lamotrigine and levetiracetam are second-generation anti-epileptic drugs used for the management of seizure disorders and some other medical conditions. In the related research article using retrospective data from an academic medical center, we analyzed 5046 samples originating from 1930 unique pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kelly E. Wood, Kendra L. Palmer, Matthew D. Krasowski
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cardiotoxicity Drug monitoring Lamotrigine Levetiracetam Neurotoxicity syndromes Pharmacokinetics Computer applications to medicine. Medical informatics R858-859.7 Science (General) Q1-390
Acceso en línea:	https://doaj.org/article/a97b3e9be04c4eb7a58f3b3bb301b0a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a97b3e9be04c4eb7a58f3b3bb301b0a5
record_format	dspace
spelling	oai:doaj.org-article:a97b3e9be04c4eb7a58f3b3bb301b0a52021-11-12T04:38:23ZData on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center2352-340910.1016/j.dib.2021.107555https://doaj.org/article/a97b3e9be04c4eb7a58f3b3bb301b0a52021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2352340921008313https://doaj.org/toc/2352-3409Lamotrigine and levetiracetam are second-generation anti-epileptic drugs used for the management of seizure disorders and some other medical conditions. In the related research article using retrospective data from an academic medical center, we analyzed 5046 samples originating from 1930 unique patients that had lamotrigine drug levels performed on serum/plasma and 4359 samples from 2451 patients that had levetiracetam drug levels performed. The data in this article provides the patient demographic, clinical location at time of drug level, and specific lamotrigine or levetiracetam serum/plasma drug level for all patients. For those instances with lamotrigine drug level greater than 14.0 mg/L or levetiracetam drug level of 80 mg/L or higher, additional data from chart review includes: indication for ordering the drug level, two main presenting signs or symptoms at time of drug level, timing of drug level (random, trough, peak, or unknown), changes in drug dosing following the drug level, concomitant therapy with valproic acid (lamotrigine only), and details related to drug overdose (if applicable). The analyzed data is provided in the supplementary tables included in this article. Volumes of test ordering by year is included in a figure. The dataset reported is related to the research article entitled “Correlation of Elevated Lamotrigine and Levetiracetam Serum/Plasma Levels with Toxicity: A Long-Term Retrospective Review at an Academic Medical Center” [K. E. Wood, K. L. Palmer, M.D. Krasowski, Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center, Toxicol. Rep. (2021) 8:1592-1598]Kelly E. WoodKendra L. PalmerMatthew D. KrasowskiElsevierarticleCardiotoxicityDrug monitoringLamotrigineLevetiracetamNeurotoxicity syndromesPharmacokineticsComputer applications to medicine. Medical informaticsR858-859.7Science (General)Q1-390ENData in Brief, Vol 39, Iss , Pp 107555- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cardiotoxicity Drug monitoring Lamotrigine Levetiracetam Neurotoxicity syndromes Pharmacokinetics Computer applications to medicine. Medical informatics R858-859.7 Science (General) Q1-390
spellingShingle	Cardiotoxicity Drug monitoring Lamotrigine Levetiracetam Neurotoxicity syndromes Pharmacokinetics Computer applications to medicine. Medical informatics R858-859.7 Science (General) Q1-390 Kelly E. Wood Kendra L. Palmer Matthew D. Krasowski Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
description	Lamotrigine and levetiracetam are second-generation anti-epileptic drugs used for the management of seizure disorders and some other medical conditions. In the related research article using retrospective data from an academic medical center, we analyzed 5046 samples originating from 1930 unique patients that had lamotrigine drug levels performed on serum/plasma and 4359 samples from 2451 patients that had levetiracetam drug levels performed. The data in this article provides the patient demographic, clinical location at time of drug level, and specific lamotrigine or levetiracetam serum/plasma drug level for all patients. For those instances with lamotrigine drug level greater than 14.0 mg/L or levetiracetam drug level of 80 mg/L or higher, additional data from chart review includes: indication for ordering the drug level, two main presenting signs or symptoms at time of drug level, timing of drug level (random, trough, peak, or unknown), changes in drug dosing following the drug level, concomitant therapy with valproic acid (lamotrigine only), and details related to drug overdose (if applicable). The analyzed data is provided in the supplementary tables included in this article. Volumes of test ordering by year is included in a figure. The dataset reported is related to the research article entitled “Correlation of Elevated Lamotrigine and Levetiracetam Serum/Plasma Levels with Toxicity: A Long-Term Retrospective Review at an Academic Medical Center” [K. E. Wood, K. L. Palmer, M.D. Krasowski, Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center, Toxicol. Rep. (2021) 8:1592-1598]
format	article
author	Kelly E. Wood Kendra L. Palmer Matthew D. Krasowski
author_facet	Kelly E. Wood Kendra L. Palmer Matthew D. Krasowski
author_sort	Kelly E. Wood
title	Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
title_short	Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
title_full	Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
title_fullStr	Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
title_full_unstemmed	Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center
title_sort	data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: experience at an academic medical center
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/a97b3e9be04c4eb7a58f3b3bb301b0a5
work_keys_str_mv	AT kellyewood dataontherelationshipbetweenlamotrigineandlevetiracetamserumplasmalevelsandtoxicityexperienceatanacademicmedicalcenter AT kendralpalmer dataontherelationshipbetweenlamotrigineandlevetiracetamserumplasmalevelsandtoxicityexperienceatanacademicmedicalcenter AT matthewdkrasowski dataontherelationshipbetweenlamotrigineandlevetiracetamserumplasmalevelsandtoxicityexperienceatanacademicmedicalcenter
_version_	1718431249736925184

Data on the relationship between lamotrigine and levetiracetam serum/plasma levels and toxicity: Experience at an academic medical center

Ejemplares similares